ALLO · Allogene Therapeutics, Inc. · Documents

Nov 7

Quarterly report 10-Q FY2024 Q3, ended Sep 30

Quarterly report for FY2024 Q3

Revenue $0 Net loss $66.29M Diluted EPS -$0.32

Oct 7

Current report 8-K Events of Oct 3

Code of ethics change or waiver

Aug 7

Current report 8-K

Financial results

Aug 7

Quarterly report 10-Q FY2024 Q2, ended Jun 30

Quarterly report for FY2024 Q2

Revenue $0 Net loss $66.36M Diluted EPS -$0.35

Jun 10

Current report 8-K Events of Jun 5

Director or officer change, or executive pay, Shareholder vote results

May 31

Current report 8-K Events of May 24

Entered into a material agreement

May 14

Current report 8-K Events of May 13

Other events

May 13

Earnings call

Q1 2024 earnings call

May 13

Current report 8-K

Financial results

May 13

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Revenue $22K ▼ 26.7% Net loss $65M Diluted EPS -$0.38

Apr 23

Proxy statement DEF 14A Meeting Jun 5, 2024

Proxy statement

Apr 23

Annual report to holders ARS

Annual report to holders

Apr 23

Proxy statement DEFA14A

Proxy statement

Mar 14

Earnings call

Q4 2023 earnings call

Mar 14

Annual report 10-K/A FY2022, ended Dec 31

Annual report for FY2022

Revenue $156K ▼ 99.9% Net loss $340.41M Diluted EPS -$2.38

Mar 14

Current report 8-K

Financial results

Mar 14

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Revenue $95K ▼ 39.1% Net loss $327.27M Diluted EPS -$2.09

Mar 14

Registration statement S-3

Registration statement

Feb 16

Current report 8-K Events of Feb 14

Earlier financial statements no longer reliable

Jan 31

Current report 8-K Events of Jan 25

Entered into a material agreement

Jan 5

Current report 8-K Events of Jan 3

Entered into a material agreement, Exit or restructuring costs, Other events

Dec 19

Current report 8-K Events of Dec 9

Other events

Nov 2

Earnings call

Q3 2023 earnings call

Nov 2

Current report 8-K

Financial results

Nov 2

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Revenue $43K ▼ 12.2% Net loss $61.32M Diluted EPS -$0.37

Oct 17

Current report 8-K/A Events of Oct 16

Director or officer change, or executive pay

Oct 16

Current report 8-K

Director or officer change, or executive pay

Aug 2

Earnings call

Q2 2023 earnings call

Aug 2

Current report 8-K

Financial results

Aug 2

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Revenue $44K ▼ 48.8% Net loss $77.99M Diluted EPS -$0.53

Jun 21

Current report 8-K Events of Jun 15

Other events

Jun 15

Current report 8-K Events of Jun 13

Shareholder vote results

Jun 14

Current report 8-K Events of Jun 9

Director or officer change, or executive pay

Jun 7

Current report 8-K Events of Jun 3

Other events

May 3

Earnings call

Q1 2023 earnings call

May 3

Current report 8-K

Financial results

May 3

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Revenue $52K ▼ 14.8% Net loss $98.7M Diluted EPS -$0.68

Apr 24

Proxy statement DEF 14A

Proxy statement

Apr 24

Annual report to holders ARS

Annual report to holders

Apr 24

Proxy statement DEFA14A

Proxy statement

Apr 20

Current report 8-K Events of Apr 18

Director or officer change, or executive pay

Mar 10

Current report 8-K

Regulation FD disclosure

Feb 28

Earnings call

Q4 2022 earnings call

Feb 28

Current report 8-K

Financial results

Feb 28

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Revenue $243K ▼ 99.4% Net loss $332.63M Diluted EPS -$2.32

Jan 3

Current report 8-K Events of Dec 27

Director or officer change, or executive pay

Nov 29

Current report 8-K

Other events

Nov 2

Earnings call

Q3 2022 earnings call

Nov 2

Current report 8-K

Financial results

Nov 2

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Revenue $49K ▲ unchanged Net loss $83.15M Diluted EPS -$0.58